BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37684154)

  • 1. Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps.
    Mandl HK; Miller JE; Beswick DM
    Otolaryngol Clin North Am; 2024 Apr; 57(2):225-242. PubMed ID: 37684154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
    Geng B; Dilley M; Anterasian C
    Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
    Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
    J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps.
    Koski RR; Hill L; Taavola K
    J Pharm Technol; 2022 Oct; 38(5):289-296. PubMed ID: 36046351
    [No Abstract]   [Full Text] [Related]  

  • 5. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review.
    Aldajani A; Alroqi A; Alromaih S; Aloulah MO; Alsaleh S
    Am J Otolaryngol; 2022; 43(6):103615. PubMed ID: 36057193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.
    Bajpai S; Marino MJ; Rank MA; Donaldson AM; O'Brien EK; Lal D
    Int Forum Allergy Rhinol; 2021 Aug; 11(8):1152-1161. PubMed ID: 33527730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps.
    Patel GB; Peters AT
    Ear Nose Throat J; 2021 Jan; 100(1):44-47. PubMed ID: 33035132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.
    Striz I; Golebski K; Strizova Z; Loukides S; Bakakos P; Hanania NA; Jesenak M; Diamant Z
    Clin Sci (Lond); 2023 May; 137(9):727-753. PubMed ID: 37199256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
    Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
    J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
    Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
    Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 13. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.
    Lelegren MJ; Son SY; Han JK; Lam KK
    Immunotherapy; 2022 Jun; 14(8):655-662. PubMed ID: 35510314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
    De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
    Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai).
    Hong HY; Chen TY; Yang QT; Sun YQ; Chen FH; Lou HF; Wang HT; Yu RL; An YF; Liu F; Wang TS; Lu MP; Qiu QH; Wang XD; Chen JJ; Meng CD; Xie ZH; Meng J; Zeng M; Xu CL; Wang Y; Yang YC; Zhang WT; Tang J; Yang YL; Xu R; Yu GD; Shi ZH; Wei X; Ye HP; Sun YN; Yu SQ; Zhang TH; Yong J; Hang W; Xu YT; Xu Y; Tan GL; Sun N; Yang G; Li YJ; Ye J; Zuo KJ; Zhang LQ; Wang XY; Yang AN; Xu YX; Liao W; Fan YP; Li HB
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(3):128-140. PubMed ID: 37019094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Molecular Therapies in Allergy and Rhinology.
    Damask CC; Ryan MW; Casale TB; Castro M; Franzese CB; Lee SE; Levy JM; Lin SY; Lio PA; Peters AT; Platt MP; White AA
    Otolaryngol Head Neck Surg; 2021 Jan; 164(1_suppl):S1-S21. PubMed ID: 33138725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics for chronic rhinosinusitis with nasal polyps.
    Bachert C; Zhang N; Cavaliere C; Weiping W; Gevaert E; Krysko O
    J Allergy Clin Immunol; 2020 Mar; 145(3):725-739. PubMed ID: 32145872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.